Mode
Text Size
Log in / Sign up
N/A Completed N=94 Treatment

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels

Source: ClinicalTrials.gov NCT01498692 ↗
Enrolled (actual)
94
Serious AEs
28.7%
Results posted
Feb 2012
Primary outcomePrimary: Target Lesion Failure (TLF) — 2.4 percentage of participants — p=<0.0001

Summary

The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions. The lesions can be located in vessels that are smaller than average-sized.

Outcome Measures

OutcomeResultp-value
PRIMARY
Target Lesion Failure (TLF)
0.0
SECONDARY
Target Lesion Failure (TLF)
0.0
SECONDARY
Target Vessel Failure (TVF)
0.0
SECONDARY
Myocardial Infarction (MI) Related to the Target Vessel
0.0
SECONDARY
All Cause Mortality
0.0
SECONDARY
Cardiac Death Related to the Target Vessel
0.0
SECONDARY
Target Lesion Revascularization (TLR)
2.1
SECONDARY
Target Lesion Revascularization TLR)
0.0
SECONDARY
Target Vessel Revascularization (TVR)
0.0
SECONDARY
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC)Definition
0.0
SECONDARY
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition
0.0
SECONDARY
Acute Technical Success
96.8
SECONDARY
Clinical Procedural Success
96.8

Eligibility Criteria

Inclusion Criteria

  • Patient must be at least 18 years of age
  • Patient (or legal guardian) understands study requirements and treatment procedures and provides written informed consent before any study-specific tests or procedures are performed
  • For patients less than 20 years of age enrolled at a Japanese site, patient and patient's legal representative must provide written informed consent before any study-specific tests or procedures are performed
  • Patient is eligible for percutaneous coronary intervention (PCI)
  • Patient has documented stable angina pectoris or documented silent ischemia; or unstable angina pectoris
  • Patient is an acceptable candidate for coronary artery bypass grafting (CABG)
  • Patient has a left ventricular ejection fraction (LVEF) >=30% as measured within 30 days prior to enrollment
  • Patient is willing to comply with all protocol-required follow-up evaluations

Angiographic Inclusion Criteria (visual estimate):

  • Target lesion must be a de novo lesion located in a native coronary artery with a visually estimated reference vessel diameter ≥2.25 mm and 1.

Exclusion Criteria

  • Patient has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute myocardial infarction (MI)
  • Patient has had a known diagnosis of recent MI (ie, within 72 hours prior to index procedure) and has elevated enzymes at time of index procedure as follows.
  • Patients are excluded if any of the following criteria are met at time of the index procedure.
  • If creatine kinase-myoglobin band (CK-MB) >2× upper limit of normal (ULN), the patient is excluded regardless of CK Total.
  • If CK-MB is 1-2× ULN, the patient is excluded if the CK Total is >2× ULN.
  • If CK Total/CK MB are not used and Troponin is, patients are excluded if the following criterion is met at time of index procedure.
  • Troponin >1× ULN with at least one of the following.
  • Patient has ischemic symptoms and ECG changes indicative of ongoing ischemia (eg, >1 mm ST segment elevation or depression in consecutive leads or new left bundle branch block [LBBB]);
  • Development of pathological Q waves in the ECG; or
  • Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.

Note: For patients with unstable angina or patients who have had a recent MI, CK Total/CK MB (or Troponin if CK Total/CK MB are not used) must be documented prior to enrolling/randomizing the patient.

  • Patient has received an organ transplant or is on a waiting list for an organ transplant
  • Patient is receiving or scheduled to receive chemotherapy within 30 days before or after index procedure
  • Patient is receiving oral or intravenous immunosuppressive therapy (ie, inhaled steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (eg, human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus)
  • Patient is receiving chronic (>=72 hours) anticoagulation therapy (eg, heparin, coumadin) for indications other than acute coronary syndrome
  • Patient has platelet count 700,000 cells/mm3
  • Patient has white blood cell (WBC) count <3,000 cells/mm3
  • Patient has documented or suspected liver disease, including laboratory evidence of hepatitis
  • Patient is on dialysis or has known renal insufficiency (ie, estimated creatinine clearance <50 ml/min by the Cockcroft Gault formula, or [(140-age)*lean body weight (in kg)]/[plasma creatinine (mg/dl)*72])
  • Patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions
  • Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within past 6 months, or has any permanent neurologic defect that may cause non-compliance with the protocol
  • Target vessel(s) or side branch has been treated with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to index procedure
  • Target vessel(s) has been treated within 10 mm proximal or distal to ta
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01498692). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search